Compare Immunovant Inc. Common Stock (IMVT) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs RLX Technology Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.33 (market cap $6.25B), while RLX Technology Inc trades at $1.72 (market cap $2.10B). The key difference: Immunovant Inc. Common Stock is far larger — about 3× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and RLX Technology Inc for 34 Days on average.
| IMVT | RLX | |
|---|---|---|
Market Cap | $6.25B | $2.10B |
Volume | 1,755,411 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $44.96 | $2.57 |
52-Week Low | $17.03 | $1.68 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $5.35B | $832.26M |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $1.73, showing no change in the latest session and recently hitting 52-week lows. The stock exhibits bearish technical signals with mixed fundamentals - revenue grew to $3.62B in 2025 with strong 21.87% net margins, but recent quarters show consistent earnings misses. Analyst coverage remains limited with a single hold rating, while cash flow trends show volatility with negative net cash flow in 2025.
RLX faces near-term headwinds from earnings underperformance and technical weakness, though valuation appears reasonable with P/E of 15.46 and P/B below 1.0. International expansion provides growth potential, but regulatory risks and margin compression require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
